ASCO® 2024 Highlights: Presenter Vignette – Daniel Petrylak

ASCO® 2024 Highlights: Presenter Vignette – Daniel Petrylak

ASCO® 2024 Highlights: Presenter Vignettes
Dr. Daniel Petrylak

Daniel Petrylak

MD

Yale School of Medicine

Abstract# 4503, 5011

4503 – Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
5011 – ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

Studies/trials discussed:

  • 4503 – Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
  • 5011 – ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
Tagged